CIK 0001595097 · Non-accelerated filer<br>Smaller reporting company
Corbus Pharmaceuticals Holdings, Inc.
Sign in to watch- Ticker
- CRBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464348039
- Phone
- 617-963-0103
- Business address
- 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
- Former names
- SAV Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,758,438
- in 2 filings, $16K under 10b5-1 plans
Net −$1,758,438. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-30 | Altmeyer Anne Director | Sale 10b5-1 | −1,392 | $7.25 | $10K | 1,391 |
| 2025-05-30 | Altmeyer Anne Director | Grant or award 10b5-1 | +4,800 | 6,191 | ||
| 2025-05-30 | Altmeyer Anne Director | Grant or award · Stock options (right to buy) 10b5-1 | +16,000 | 16,000 | ||
| 2025-05-30 | HOLMER ALAN F Director | Grant or award | +4,800 | 10,629 | ||
| 2025-05-30 | HOLMER ALAN F Director | Grant or award · Stock options (right to buy) | +16,000 | 16,000 | ||
| 2025-05-30 | Jacques Rachelle Suzanne Director | Grant or award | +4,800 | 7,583 | ||
| 2025-05-30 | Jacques Rachelle Suzanne Director | Grant or award · Stock options (right to buy) | +16,000 | 16,000 | ||
| 2025-03-06 | Smethurst Dominic Chief Medical Officer | Sale | −6,393 | $6.78 | $43K | 70,807 |
| 2025-02-14 | Moran Sean F. Chief Financial Officer | Sale 10b5-1 | −2,792 | $8.76 | $24K | 73,313 |
| 2025-02-14 | Cohen Yuval Chief Executive Officer | Sale 10b5-1 | −7,134 | $8.76 | $62K | 138,187 |
| 2025-01-31 | Smethurst Dominic Chief Medical Officer | Grant or award | +27,200 | 77,200 | ||
| 2025-01-31 | Smethurst Dominic Chief Medical Officer | Grant or award · Stock options (right to buy) | +91,200 | 91,200 | ||
| 2025-01-31 | Moran Sean F. Chief Financial Officer | Grant or award | +27,500 | 76,105 | ||
| 2025-01-31 | Moran Sean F. Chief Financial Officer | Grant or award · Stock options (right to buy) | +92,500 | 92,500 | ||
| 2025-01-31 | Cohen Yuval Chief Executive Officer | Grant or award | +68,100 | 145,321 | ||
| 2025-01-31 | Cohen Yuval Chief Executive Officer | Grant or award · Stock options (right to buy) | +228,800 | 228,800 | ||
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +45,085 | $17.48 | $788K | 2,070,085 |
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +25,943 | $18.36 | $476K | 2,096,028 |
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +66,088 | $19.61 | $1.3M | 2,162,116 |
| 2024-09-20 | Cormorant Asset Management, LP 10% owner | Purchase | +139,551 | $20.42 | $2.8M | 2,301,667 |
Page 4 of 10 · 200 trades